Option Agreement Sample Contracts

BOULEVARD ACQUISITION CORP II CAYMAN HOLDING Co – Estre Ambiental, Inc. EXECUTIVE AND TEAM MEMBER SHARE OPTION GRANT NOTICE AND OPTION AGREEMENT (2017 Omnibus Incentive Plan) (July 12th, 2018)

Congratulations! As a key leader in our business, you are in a position to have significant influence on the performance and success of Estre Ambiental, Inc. (f/k/a Boulevard Acquisition Corp II Cayman Holding Company), a Cayman Islands exempted company (the "Company"). I am pleased to inform you that, in recognition of the role you play in our collective success, you have been granted an option to purchase ordinary shares of the Company. This award is subject to the terms and conditions of the Estre Ambiental, Inc. 2017 Omnibus Incentive Plan, this Grant Notice, and the following Option Agreement. The details of this award are indicated below.

Acura Pharmaceuticals – License, Commercialization and Option Agreement (June 7th, 2018)

This License, Commercialization and Option Agreement ("Agreement") is made and entered into as of March 16, 2017 (the "Effective Date") by and between MainPointe Pharmaceuticals, LLC, with offices at 333 East Main Street, Suite 220, Louisville, Kentucky 40202 ("MainPointe"), and Acura Pharmaceuticals, Inc., with offices at 616 N. North Court, Palatine IL 60067 ("Acura"). MainPointe and Acura each are referred to herein as a "Party" and collectively as the "Parties."

Metalline Mining Company – Option Agreement (June 7th, 2018)

Contratistas de Sierra Mojada S.A. de C.V. c/o Silver Bull Resources Inc. of 1610 - 777 Dunsmuir Street, Vancouver, British Columbia, Canada, V7Y 1K4

Sunlands Online Education Group – Option Agreement (May 22nd, 2018)

This Option Agreement (hereinafter referred to as "Agreement") was made as of the 21st day of May, 2018 in Beijing, the People's Republic of China ("PRC") by and among the parties (hereinafter referred to as "Parties") as follows:

Puhui Wealth Investment Management Co., Ltd. – Equity Option Agreement (May 21st, 2018)

This Equity Option Agreement (this "Agreement") is executed by and among the following Parties as of January, 30th, 2018 in Beijing, the People's Republic of China ("China" or the "PRC"):

Renren Inc. – Equity Option Agreement (May 14th, 2018)

This Equity Option Agreement (this "Agreement") is entered in Beijing, the People's Republic of China ("PRC," excluding the Hong Kong Special Administrative Region, the Macao Special Administrative Region and Taiwan, for the purposes of this Agreement) and dated August 18 of 2017, by and between the following parties:

Alcobra Ltd. – Development and Option Agreement (May 14th, 2018)

This Development and Option Agreement (this "Agreement"), dated as of 1 January 2018 (the "Effective Date"), is made by and between CureVac AG, a German stock corporation with offices at Paul-Ehrlich-Strasse 15, 72076 Tubingen, Germany ("CureVac"), and Arcturus Therapeutics Inc., a Delaware corporation with offices at 10628 Science Center Drive # 200, San Diego, CA 92121, USA ("Arcturus"). Each of CureVac and Arcturus may be referred to herein as a "Party" or together as the "Parties".

Renren Inc. – Equity Option Agreement (May 14th, 2018)

This Equity Option Agreement (this "Agreement") is entered in Beijing, the People's Republic of China ("PRC," excluding the Hong Kong Special Administrative Region, the Macao Special Administrative Region and Taiwan, for the purposes of this Agreement) and date August 18 of 2017, by and between the following parties:

Renren Inc. – Equity Option Agreement (May 14th, 2018)

This Equity Option Agreement (this "Agreement") is entered in Beijing, the People's Republic of China ("PRC," excluding the Hong Kong Special Administrative Region, the Macao Special Administrative Region and Taiwan, for the purposes of this Agreement) and dated August 18 of 2017, by and between the following parties:

Renren Inc. – Equity Option Agreement (May 14th, 2018)

This Equity Option Agreement (this "Agreement") is entered in Beijing, the People's Republic of China ("PRC," excluding the Hong Kong Special Administrative Region, the Macao Special Administrative Region and Taiwan, for the purposes of this Agreement) and dated August 18 of 2017, by and between the following parties:

Acelrx Pharmaceuticals – Form of Performance-Based Option Agreement (May 10th, 2018)

AcelRx Pharmaceuticals, Inc. (the "Company"), pursuant to its 2011 Equity Incentive Plan (the "Plan"), hereby grants to Optionholder an option to purchase the number of shares of the Company's Common Stock set forth below. This option is subject to all of the terms and conditions as set forth herein and in the Option Agreement, the Plan, and the Notice of Exercise, all of which are attached hereto and incorporated herein in their entirety.

Tronox Enters Option Agreement to Acquire Majority of Advanced Metal Industries Co. Jazan Slagger Operations (May 10th, 2018)

STAMFORD, Conn., May 9, 2018 /PRNewswire/ -- Tronox Limited (NYSE: TROX) ("Tronox" or the "Company"), a global mining and inorganic chemicals company, today announced it has entered into an Option Agreement with Advanced Metal Industries Cluster Company Limited ("AMIC") to acquire 90 percent of AMIC's ownership in a titanium slag smelter facility (the "Slagger") located in The Jazan City for Primary and Downstream Industries in the Kingdom of Saudi Arabia. The execution of the Option Agreement occurred shortly after Tronox and AMIC entered into a Technical Services Agreement to provide certain technical assistance to AMIC to facilitate start-up of the Slagger. AMIC is equally owned by The National Titanium Dioxide Company Limited ("Cristal") and National Industrialization Company, also known as Tasnee.

Long Island Iced Tea Corp. – Amended and Restated Loan and Option Agreement (May 9th, 2018)

Court Cavendish Ltd, a company incorporated in England and Wales under no. 04290684, having its registered address at The Care House, Randalls Way, Leatherhead, Surrey, KT22 7TW (the "Lender").

TRIPADVISOR, INC. OPTION AGREEMENT (Domestic) (May 8th, 2018)

THIS OPTION AGREEMENT (this "Agreement"), dated as of the grant date specified on the Grant Details referenced below (the "Grant Date"), between TripAdvisor, Inc., a Delaware corporation (the "Company"), and the employee, director or consultant of the Company or one of its Affiliates or Subsidiaries designated on the Grant Details (as defined below) (the "Eligible Individual"), describes the terms of an award of an Option to the Eligible Individual by the Company (the "Award").

Atara Biotherapeutics – Atara Biotherapeutics, Inc. 2018 Inducement Plan Option Agreement (Nonstatutory Stock Option) (May 8th, 2018)

Pursuant to your Stock Option Grant Notice ("Grant Notice") and this Option Agreement (this "Option Agreement"), Atara Biotherapeutics, Inc. (the "Company") has granted you an option to purchase the number of shares of the Company's Common Stock indicated in your Grant Notice at the exercise price indicated in your Grant Notice (your "option"). Your option is granted to you effective as of the date of grant set forth in the Grant Notice (the "Date of Grant"). Your option is granted as a material inducement to you entering into employment with the Company (within the meaning of NASDAQ Listing Rule 5635(c)(4)). If there is any conflict between the terms in this Option Agreement and the Plan, the terms of the Plan will control. Capitalized terms not explicitly defined in this Option Agreement or in the Grant Notice but defined in the Plan will have the same definitions as in the Plan.

TRIPADVISOR, INC. OPTION AGREEMENT (International) (May 8th, 2018)

THIS OPTION AGREEMENT (this "Agreement"), dated as of the Grant Date specified on the Grant Details referenced below (the "Grant Date"), between TripAdvisor, Inc., a Delaware corporation (the "Company"), and the employee, director or consultant of the Company or one of its Affiliates or Subsidiaries designated on the Grant Details (as defined below) (the "Eligible Individual"), describes the terms of an award of an Option to the Eligible Individual by the Company.

Form of Option Agreement (May 3rd, 2018)

This Option Agreement (Agreement) entered into as of [GRANT DATE] (the Grant Date), by and between Fluor Corporation, a Delaware corporation (the Company), and you (Grantee or you) evidences the grant to Grantee of a Stock Option (Option) under the Fluor Corporation 2017 Performance Incentive Plan (the Plan). Capitalized terms used in this Agreement and not defined herein have the meaning set forth in the Plan.

Smart Energy Solutions Inc – Feasibility Study and Option Agreement (April 30th, 2018)

This Research and Option Agreement ("Agreement") made in Jerusalem and bearing the effective date of September 7th, 2017 ("Effective Date"), is by and between YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD., of Hi Tech Park, Edmond J. Safra Campus, Givat Ram, Jerusalem 91390, Israel ("Yissum") and Carina Powder LTD, of 20 Raul Wallenberg Tel Aviv (the "Company").

PPDAI Group Inc. – Restated Option Agreement (April 27th, 2018)

THIS RESTATED OPTION AGREEMENT (this "Agreement"), dated this 21st day of March, 2018, is entered into in Shanghai, the People's Republic of China (the "PRC") by and among:

Phoenix New Media Ltd. - ifeng.com – Exclusive Equity Option Agreement of Beijing Chenhuan Technology Co., Ltd. By and Among Wu Haipeng He Yansheng Beijing Chenhuan Technology Co., Ltd. And Qieyiyou (Beijing) Information Technology Co., Ltd. January 13, 2014 (April 26th, 2018)

This Exclusive Equity Option Agreement (the Agreement) is entered into by the following parties on January 13, 2014 in Beijing, the Peoples Republic of China (PRC or China):

Unity Biotechnology, Inc. – Compound Library and Option Agreement (April 23rd, 2018)

This Compound Library and Option Agreement (the Agreement), dated as of February 2nd, 2016 (the Signing Date), is made by and between Ascentage Pharma Group Corp. Ltd., a Hong Kong corporation (Ascentage), with a business address at 11/F, AXA CENTRE, Gloucester Road, Wanchai, Hong Kong, and Unity Biotechnology, Inc., a Delaware corporation (Unity), with a business address at 1700 Owens Street, Suite 535, San Francisco, California 95158. Ascentage and Unity are sometimes referred to herein as individually as a party and collectively as the parties.

Heatwurx, Inc. – License Option Agreement With Concert (April 17th, 2018)
Heatwurx, Inc. – License Option Agreement With Concert (April 16th, 2018)
Network Cn Inc – Amendment No. 12 to Note Exchange and Option Agreement (April 16th, 2018)

This AMENDMENT NO. 12 to the NOTE EXCHANGE AND OPTION AGREEMENT is entered into as of December 28, 2017 (this "Amendment"), by and among KEYWIN HOLDINGS LIMITED, a British Virgin Islands company ("Keywin"), and NETWORK CN INC., a Delaware corporation (the "Company"). Each of the parties hereto is referred to as a "Party" and collectively as the "Parties." Capitalized terms used, but not otherwise defined, herein have the meanings ascribed to such terms in the Original Agreement (as defined below).

Hilton Worldwide Holdings Inc. – Master Amendment and Option Agreement (April 9th, 2018)

THIS MASTER AMENDMENT AND OPTION AGREEMENT (this Agreement), dated as of April 9, 2018, is between Hilton Worldwide Holdings Inc., a Delaware corporation (the Company), HNA Tourism Group Co., Ltd., a Peoples Republic of China (PRC) company (HNA), and HNA HLT Holdco I LLC, a Delaware limited liability company (the Selling Stockholder).

Construction Partners, Inc. – Option Agreement (April 6th, 2018)

THIS OPTION AGREEMENT (this Option Agreement) is made and entered into as of the 7th day of March, 2017 (the Date of Grant) by and between Fred J. Smith, III (Holder) and SunTx CPI Growth Company, Inc., a Delaware corporation (Issuer).

Option Agreement (April 5th, 2018)

Pursuant to the Stock Incentive Plan (the "Plan") of NIKE, Inc., an Oregon corporation (the "Company"), the Company grants to the individual listed below (the "Participant") the right and the option (the "Option") to purchase all or any part of the total shares of the Company's Class B Common Stock ("Shares") granted per the terms and conditions of this agreement between the Company and the Participant (this "Agreement"). By accepting this Option grant, the Participant agrees to all of the terms and conditions of the Plan, the Agreement and any Appendices included with the Agreement. Capitalized terms not explicitly defined in this Agreement but defined in the Plan shall have the same definitions as in the Plan.

Unity Biotechnology, Inc. – Compound Library and Option Agreement (April 5th, 2018)

This Compound Library and Option Agreement (the Agreement), dated as of February 2nd, 2016 (the Signing Date), is made by and between Ascentage Pharma Group Corp. Ltd., a Hong Kong corporation (Ascentage), with a business address at 11/F, AXA CENTRE, Gloucester Road, Wanchai, Hong Kong, and Unity Biotechnology, Inc., a Delaware corporation (Unity), with a business address at 1700 Owens Street, Suite 535, San Francisco, California 95158. Ascentage and Unity are sometimes referred to herein as individually as a party and collectively as the parties.

Unity Biotechnology, Inc. – First Amendment to Compound Library and Option Agreement (April 5th, 2018)

This Amendment (the Amendment), dated as of March 28, 2018 (the Amendment Effective Date) is made by and between Ascentage Pharma Group Corp. Ltd., a Hong Kong corporation (Ascentage), with a business address at 11/F, AXA CENTRE, Gloucester Road, Wanchai, Hong Kong, and Unity Biotechnology, Inc., a Delaware corporation (Unity), with a business address at 3280 Bayshore Blvd, Suite 100, Brisbane, California 95002. Ascentage and Unity are sometimes referred to herein as individually as a Party and collectively as the Parties.

Novocure Ltd – Form of Performance Option Agreement for Israel Novocure Limited (April 4th, 2018)

AGREEMENT (this "Agreement"), dated as of [____________] between NovoCure Limited, a Jersey Isle company (the "Company" and, collectively with its controlled Affiliates, the "Employer"), and [________________] (the "Participant").

Evaluation and Option Agreement for a Patent License (April 2nd, 2018)

This Evaluation and Option Agreement for a Patent License ("Agreement"), dated as of February 1, 2018 ("Effective Date"), is by and between Actigen Limited ("Patent Holder") Pharmstandard International, S.A. ("Prospective Licensor") and Argos Therapeutics, Inc. ("Prospective Sublicensee").

Unity Biotechnology, Inc. – Compound Library and Option Agreement (March 23rd, 2018)

This Compound Library and Option Agreement (the Agreement), dated as of February 2nd, 2016 (the Signing Date), is made by and between Ascentage Pharma Group Corp. Ltd., a Hong Kong corporation (Ascentage), with a business address at 11/F, AXA CENTRE, Gloucester Road, Wanchai, Hong Kong, and Unity Biotechnology, Inc., a Delaware corporation (Unity), with a business address at 1700 Owens Street, Suite 535, San Francisco, California 95158. Ascentage and Unity are sometimes referred to herein as individually as a party and collectively as the parties.

Surface Oncology, Inc. – Development and Option Agreement (March 23rd, 2018)

THIS DEVELOPMENT AND OPTION AGREEMENT (the Agreement) is made effective as of July 3, 2014 (the Effective Date), by and between Adimab, LLC, a Delaware limited liability company having an address at 7 Lucent Drive, Lebanon, NH 03766 (Adimab), and Surface Oncology, Inc., a Delaware corporation having an address at 25 First Street, Suite 303, Cambridge, MA 02141 (Surface).

Hilton Grand Vacations Inc. – Master Amendment and Option Agreement (March 13th, 2018)

THIS MASTER AMENDMENT AND OPTION AGREEMENT (this Agreement), dated as of March 13, 2018, is between Hilton Grand Vacations Inc., a Delaware corporation (the Company), HNA Tourism Group Co., Ltd., a Peoples Republic of China (PRC) company (HNA), and HNA HLT Holdco I LLC, a Delaware limited liability company (the Selling Stockholder).

2018 OPTION AGREEMENT (Non-Qualified Stock Option) (CA Employee) (March 9th, 2018)

This Option Agreement is made as of the __ day of March 2018 between Myers Industries, Inc., an Ohio corporation (hereinafter called the "Company"), and <<full_name>> an employee of the Company or one or more of its Subsidiaries (hereinafter called the "Employee").